Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks

David T Arnold, Charmaine Donald, Max Lyon, Fergus W Hamilton, Anna J Morley, Marie Attwood, Alexandra Dipper, Shaney L Barratt

Research output: Contribution to journalArticle (Academic Journal)peer-review

38 Downloads (Pure)


INTRODUCTION: Acute presentations of COVID-19 infection vary, ranging from asymptomatic carriage through to severe clinical manifestations including acute respiratory distress syndrome (ARDS). Longer term sequelae of COVID-19 infection includes lung fibrosis in a proportion of patients. Krebs von den Lungen 6 (KL-6) is a mucin like glycoprotein that has been proposed as a marker of pulmonary epithelial cell injury. We sought to determine whether KL-6 was a marker of 1) the severity of acute COVID-19 infection, or 2) the persistence of symptoms/radiological abnormalities at medium term follow up.

METHODS: Prospective single centre observational study.

RESULTS: Convalescent KL-6 levels were available for 93 patients (male 63%, mean age 55.8 years) who attended an 12-week follow up appointment after being admitted to hospital with COVID-19. For 67 patients a baseline KL-6 result was available for comparison. There was no significant correlations between baseline KL-6 and the admission CXR severity score or clinical severity NEWS score. Furthermore, there was no significant difference in the baseline KL-6 level and an initial requirement for oxygen on admission or the severity of acute infection as measured at 28 days. There was no significant difference in the 12-week KL-6 level and the presence or absence of subjective breathlessness but patients with abnormal CT scans at 12 weeks had significantly higher convalescent KL-6 levels compared to the remainder of the cohort (median 1101 IU/ml vs 409 IU/ml).

CONCLUSIONS: The association between high KL-6 levels at 12 weeks and persisting CT abnormalities (GGO/fibrosis), is a finding that requires further exploration. Whether KL-6 may help differentiate those patients with persisting dyspnoea due to complications rather than deconditioning or dysfunctional breathing alone, is an important future research question.

Original languageEnglish
Article numbere0249607
Number of pages10
JournalPLoS ONE
Issue number4
Publication statusPublished - 29 Apr 2021

Structured keywords

  • Covid19


  • Adult
  • Aged
  • Biomarkers/blood
  • COVID-19/blood
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mucin-1/blood
  • Prospective Studies
  • SARS-CoV-2/isolation & purification
  • Severity of Illness Index
  • Tomography, X-Ray Computed


Dive into the research topics of 'Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks'. Together they form a unique fingerprint.

Cite this